Operator: Good afternoon and welcome ladies and gentlemen to Cytokinetics' Fourth Quarter 2022 Conference Call.
Keep Reading →
March 6 - News, Transcripts - Comments
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here.
Keep Reading →
October 18 - Hedge Fund Investor Letters, News - Comments
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market...
Keep Reading →
December 12 - Hedge Funds, News - Comments
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Keep Reading →
October 18 - Hedge Funds, News - Comments
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need ...
Keep Reading →
July 6 - Hedge Funds, News - Comments
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Keep Reading →
April 20 - Hedge Funds, News - Comments
In this article, we will present the 10 best stocks to invest in according to the billionaire biotech hedge fund manager Joe Edelman.
Keep Reading →
December 19 - Hedge Funds, News - Comments
Small- and mid-cap biotech and pharmaceutical companies represent some of the most compelling gambles available on the market.
Keep Reading →
November 29 - Hedge Fund Analysis, Hedge Funds, News - Comments
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Keep Reading →
September 28 - Hedge Funds, News - Comments
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Keep Reading →
July 20 - Hedge Funds, News - Comments
In this article you are going to find out whether hedge funds think Cytokinetics, Inc. (NASDAQ:CYTK) is a good investment right now.
Keep Reading →
June 16 - Hedge Funds, News - Comments
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio...
Keep Reading →
December 10 - Hedge Funds, News - Comments
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th.
Keep Reading →
November 1 - Hedge Funds, News - Comments
BOSTON (Reuters) - Balyasny Asset Management, a Chicago-based hedge fund that shed $4 billion in assets last year and cut 20% of its staff, was back in positive territory for ...
Keep Reading →
July 15 - Hedge Funds, Insider Trading - Comments
Hedge fund interest in Cytokinetics, Inc. (NASDAQ:CYTK) shares was flat at the end of last quarter and it wasn't that high to begin with. This is usually a negative indicator.
Keep Reading →
June 27 - Hedge Funds, News - Comments
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity.
Keep Reading →
December 22 - Hedge Funds, News - Comments
Please follow Biotechnology Value Fund LP (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Biotechnology Value Fund LP or update...
Keep Reading →
December 1 - Hedge Funds - Comments
You can access the original SEC filing by clicking here.
Keep Reading →
May 15 - Hedge Funds - Comments
"U.S. stocks retreated on Tuesday as a spate of tepid corporate earnings weighed on the broader market.
Keep Reading →
April 18 - Commodities, Gold, Market Movers, News, Tech - Comments
Looking for high-potential stocks? Just follow the big players within the hedge fund industry.
Keep Reading →
December 9 - Hedge Funds, News - Comments
Mark Lampert's Biotechnology Value Fund has filed a Form 13G on Cytokinetics, Inc. (NASDAQ:CYTK), one of its top-10 holdings at the end of 2015.
Keep Reading →
March 6 - Hedge Funds, News - Comments
Before we spend many hours researching a company, we'd like to analyze what hedge funds and billionaire investors think of the stock first.
Keep Reading →
November 26 - Hedge Funds, News - Comments
Below is the Cytokinetics, Inc.
Keep Reading →
January 9 - Earnings Report, News - Comments
In another round of filings with the Securities and Exchange Commission, Steven Cohen and his fund, SAC Capital Advisors, have disclosed 4 new moves: reductions in the ownership...
Keep Reading →
April 9 - Hedge Funds, News - Comments
Mark Lampert, the founder and manager of Biotechnology Value Fund, is bullish on Cytokinetics, Inc. (NASDAQ:CYTK).
Keep Reading →
March 26 - Hedge Funds, News - Comments
At the moment, there are many indicators market participants can use to watch their holdings. Two of the most under-the-radar are hedge fund and insider trading activity.
Keep Reading →
September 17 - News - Comments
Now, according to many investors, hedge funds are assumed to be overrated, outdated investment tools of an era lost to time.
Keep Reading →
September 17 - News - Comments
Just after the successful acquisition of Onyx Pharmaceuticals and positive results on AMG-145, a cholesterol-lowering experimental drug, Amgen, Inc.
Keep Reading →
September 11 - News - Comments
Before the market opened last Tuesday, Cytokinetics, Inc. (NASDAQ:CYTK) and Amgen, Inc.
Keep Reading →
September 10 - News - Comments
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
September 9 - News - Comments
College football arrived in a big way over the past week or so, with plenty of big plays already.
Keep Reading →
September 7 - News - Comments
In the eyes of many investors, hedge funds are viewed as overrated, old investment vehicles of an era lost to time.
Keep Reading →
September 6 - News - Comments
In the 21st century investor’s toolkit, there are many metrics shareholders can use to monitor stocks.
Keep Reading →
September 3 - News - Comments
"Bubble" can be a provocative word in investing circles. Think of all that comes to mind when you hear it -- perhaps other words like over-hyped, overvalued, risky, etc.
Keep Reading →
August 27 - News - Comments
In the eyes of many of your peers, hedge funds are seen as useless, old investment tools of a forgotten age.
Keep Reading →
August 22 - News - Comments
Healthcare is the most happening industry these days with new drugs on the line and investors injecting cash into companies with greater speculative growth.
Keep Reading →
August 3 - News - Comments
Small cap stocks are a bit riskier, but offer more growth than the stable large cap ones. The biotech sector in U.S.
Keep Reading →
July 17 - News - Comments
Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry.
Keep Reading →
July 12 - News - Comments
To the average investor, there are many gauges shareholders can use to monitor stocks. Two of the most underrated are hedge fund and insider trading movement.
Keep Reading →
July 8 - News - Comments
Cytokinetics, Inc. (NASDAQ:CYTK) was in 8 hedge funds' portfolio at the end of March.
Keep Reading →
June 24 - News - Comments
Is Cytokinetics, Inc. (NASDAQ:CYTK) the right pick for your portfolio? Prominent investors are in a bullish mood.
Keep Reading →
June 17 - News - Comments
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was in 12 hedge funds' portfolio at the end of March.
Keep Reading →
June 14 - News - Comments
BioDelivery Sciences International, Inc.
Keep Reading →
June 13 - News - Comments
Is Pain Therapeutics, Inc. (NASDAQ:PTIE) a buy, sell, or hold? The smart money is in a bearish mood.
Keep Reading →
June 10 - News - Comments
A failing heart is a lot like a glass Heinz Ketchup bottle. Squeezing the bottle isn't very efficient, so you smack that strategically placed '57,' and still no condiment. ...
Keep Reading →
April 29 - News - Comments
In today’s marketplace, there are a multitude of indicators market participants can use to analyze their holdings.
Keep Reading →
April 15 - News - Comments
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) a marvelous investment today? Money managers are becoming less confident.
Keep Reading →
April 13 - News - Comments
Is Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) a buy, sell, or hold? The best stock pickers are taking a bearish view.
Keep Reading →
April 12 - News - Comments
Every week, I take a look at three companies that beat market expectations, since I believe that it's the biggest factor in a stock beating the market.
Keep Reading →
February 11 - News - Comments